JB Pharma posted a solid set of earnings for the third quarter, reflecting steady execution and resilient demand across its core therapeutic segments. The pharmaceutical company reported a 22 percent year-on-year increase in net profit to Rs. 198 crore, supported by operational efficiencies, a favourable product mix, and sustained traction in key domestic and international markets. The results highlight JB Pharma’s ability to navigate cost pressures while maintaining growth momentum, even as the broader pharmaceutical industry faces regulatory scrutiny and pricing challenges.